JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$3.58B |
| 2 |
Vanguard Short-Term Treasury ETF
VGSH
|
+$2.7B |
| 3 |
Apple
AAPL
|
+$1.71B |
| 4 |
Schwab Short-Term US Treasury ETF
SCHO
|
+$1.57B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.51B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.51B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$920M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$817M |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$794M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.23% |
| 2 | Technology | 15.68% |
| 3 | Financials | 11.13% |
| 4 | Consumer Discretionary | 9.78% |
| 5 | Healthcare | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4351
Silicon Motion
SIMO
$9.33B
| $680K | ﹤0.01% |
10,604
-409
| -4% | -$26.9K |
2015 Q1
25 quarters
|
|
|
NPKI
4352
NPK International
NPKI
$1B
| $679K | ﹤0.01% |
196,096
-137,197
| -41% | -$466K |
2016 Q4
18 quarters
|
|
4353
Eterna Therapeutics
ERNA
$3.45M
| $676K | ﹤0.01% |
+5
| New | +$720K |
2021 Q2
0 quarters
|
|
4354
ALX Oncology
ALXO
$180M
| $675K | ﹤0.01% |
12,345
+2,413
| +24% | +$144K |
2020 Q3
3 quarters
|
|
|
GPACU
4355
DELISTED
Global Partner Acquisition Corp II Unit
GPACU
| $674K | ﹤0.01% |
68,092
| – | – |
2021 Q1
1 quarter
|
|
4356
American Outdoor Brands
AOUT
$202M
| $670K | ﹤0.01% |
19,077
-19,347
| -50% | -$571K |
2020 Q3
3 quarters
|
|
4357
CALL
Clover Health Investments
CLOV
$2.25B
| $666K | ﹤0.01% |
+50,000
| New | +$491K |
2021 Q2
0 quarters
|
|
4358
Arrow Financial
AROW
$690M
| $664K | ﹤0.01% |
20,168
-22,316
| -53% | -$732K |
2016 Q4
18 quarters
|
|
4359
Kamada
KMDA
$473M
| $663K | ﹤0.01% |
113,787
-39,375
| -26% | -$236K |
2020 Q4
2 quarters
|
|
4360
EVI Industries
EVI
$248M
| $661K | ﹤0.01% |
23,277
+566
| +2% | +$16.6K |
2017 Q4
14 quarters
|
|
4361
Evogene
EVGN
$6.88M
| $660K | ﹤0.01% |
19,289
-723
| -4% | -$28.3K |
2020 Q4
2 quarters
|
|
|
XXII
4362
22nd Century Group
XXII
$605K
| – | – |
0
| – | – |
2018 Q2
12 quarters
|
|
|
MORF
4363
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $660K | ﹤0.01% |
11,505
+2,874
| +33% | +$158K |
2019 Q3
7 quarters
|
|
|
NEXN
4364
Nexxen International
NEXN
$517M
| $656K | ﹤0.01% |
+32,970
| New | +$618K |
2021 Q2
0 quarters
|
|
4365
VistaGen Therapeutics
VTGN
$12.5M
| $656K | ﹤0.01% |
+6,941
| New | +$514K |
2021 Q2
0 quarters
|
|
4366
Collegium Pharmaceutical
COLL
$711M
| $655K | ﹤0.01% |
27,678
-27,143
| -50% | -$627K |
2017 Q3
15 quarters
|
|
|
HES
4367
CALL
DELISTED
Hess
HES
| $655K | ﹤0.01% |
7,500
| – | – |
2020 Q2
4 quarters
|
|
4368
Titan International
TWI
$439M
| $653K | ﹤0.01% |
+77,132
| New | +$752K |
2021 Q2
0 quarters
|
|
4369
WisdomTree
WT
$3.64B
| $653K | ﹤0.01% |
105,370
-84,911
| -45% | -$560K |
2014 Q2
28 quarters
|
|
4370
Park Aerospace
PKE
$646M
| $649K | ﹤0.01% |
43,527
-22,951
| -35% | -$331K |
2014 Q4
26 quarters
|
|
|
DVAX
4371
DELISTED
Dynavax Technologies
DVAX
| $648K | ﹤0.01% |
65,754
+2,890
| +5% | +$26.3K |
2016 Q3
19 quarters
|
|
|
CYBE
4372
DELISTED
Cyberoptics Corp
CYBE
| $648K | ﹤0.01% |
15,830
-17,218
| -52% | -$534K |
2019 Q1
9 quarters
|
|
4373
CALL
Sabre
SABR
$803M
| $646K | ﹤0.01% |
51,800
+39,300
| +314% | +$553K |
2020 Q2
4 quarters
|
|
4374
Quince Therapeutics
QNCX
$31.2M
| $645K | ﹤0.01% |
61
+17
| +39% | +$143K |
2019 Q2
8 quarters
|
|
4375
Codexis
CDXS
$149M
| $644K | ﹤0.01% |
28,402
-91,488
| -76% | -$1.98M |
2017 Q3
15 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2021 Portfolio in Review
As of Q2 2021, JP Morgan Chase held 6,872 positions worth $838B, up 12% from $749B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase deployed $31.1B of net new capital in Q2 2021, opening 693 new positions and adding to 2,351 existing holdings. Its largest new stake was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 25,313,889 shares worth $358M.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was iShares 20+ Year Treasury Bond ETF, an estimated $1.51B trimmed.
- JP Morgan Chase's largest Q2 2021 buy was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 25,313,889 shares worth $358M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q2 2021, an estimated $3.58B increase.
- JP Morgan Chase's biggest Q2 2021 reduction was iShares 20+ Year Treasury Bond ETF, cutting an estimated $1.51B.
- JP Morgan Chase fully exited INPHI CORPORATION in Q2 2021, selling an estimated $333M.
- JP Morgan Chase's ten largest holdings make up 16% of its $838B portfolio in Q2 2021.
- JP Morgan Chase opened 693 new positions and closed 449 in Q2 2021.
- JP Morgan Chase's portfolio value rose 12% quarter-over-quarter to $838B.
Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.